Board of Directors

Mr. Rakesh Bhargava (Non- Executive Chairman)

Mr. Rakesh Bhargava is the former Non-Executive Chairman of Fresenius Kabi Oncology Limited. Earlier, he was the Managing Director & CEO of Fresenius Kabi India Private Limited. He has served as a member of the Board of Directors of Fresenius Kabi Thailand, Fresenius Kabi Singapore, Fresenius Kabi Malaysia, and as Legal Supervisor of Fresenius Kabi Taiwan. He has almost 2 decades of rich experience in the pharmaceutical industry. Prior to assuming a position in Fresenius Kabi, he was the Managing Director of Lupin Chemicals (Thailand) Ltd. He has also worked with Imperial Chemical Industry plc U.K.’s Pharmaceutical Business (predecessor of Astra Zeneca) in the capacity of General Manager for India.

Mr. Bhargava is a member of CII National Committee on Drugs and Pharmaceuticals, former member of the Executive Committee of  "Oraganization of Pharmaceutical Producers of India" (OPPI) and immediate Past President of  "The Pharmaceutical Form-Fill-Seal Association of India". He is on the Advisory Board of Pharmabiz, and a Board Member of the Centre for Research on Nutrition Support Systems (CRNSS). Mr. Rakesh Bhargava is an MBA from Indian Institute of Management, Ahmedabad and a Bachelor of Technology [Chemical Engineering] from Indian Institute of Technology, Kanpur.

Ms. Maria Gobbi (Managing Director)

Ms. Maria Gobbi holds a degree in 'Chemical Engineering' from the University of Politecnico, Milan, Italy. She has experience of three decades in pharmaceutical industry at international level.

Earlier she was the General Manager of Antibioticos Spain and VP of Sales and Marketing of Alpharma Aps, a USA based company located in Scandinavian Countries and manufacturing mainly Antibiotics, both APIs and Finished Products. Ms. Gobbi is also the Managing Director of Fresenius Kabi Anti-Infectives and a Board Member at Fresenius Kabi Italy.

In her illustrious professional career, she has handled many critical assignments related to accessing new markets, diversifying customer's portfolio, optimizing manufacturing set-up, driving the companies toward FDA approved status etc. She has been also playing a key role in the revival plan for Kalyani facility of the Company.

Mr. Nikhil Kulshreshtha (Director & Secretary)

Mr. Nikhil Kulshreshtha is a member of the Institute of Company Secretaries of India (ICSI). He has also attended management and leadership programs from national and international management institutions like IIM (Ahmedabad), NUS, Singapore etc. He has been associated with the Company since the year 2007. Before his induction on the Board, he was holding the position of EVP-GRC & Company Secretary and was responsible for Legal, Compliances, Secretarial, Internal Audit and Administration functions of the Company. Mr. Kulshreshtha has overall 25 years of professional experience. During this period, he has worked in different capacities with large Indian conglomerates like Bharti Airtel, HCL and DLF, handling secretarial, legal, commercial, accounts and administrative functions. In his professional career, he has acquired extensive hands on experience in handling Mergers & Acquisition, Legal Due Diligence, Integration, IPO's & ESOP formulation and Statutory Compliances etc.

Dr. Michael Schönhofen (Non-Executive Director)

Dr. Michael Schönhofen holds a Doctorate degree from Gesellschaft für Schwerionenforschung, Darmstadt, Germany and College of Advanced Technology, Darmstadt. Dr. Schönhofen has been associated with the Fresenius group since 1991 in various functions and responsibilities. He is currently holding the position of President, Production & Technology and Member of the Board of Fresenius Kabi AG.

Mr. D. G. Shah (Non-Executive Director)

Mr Dilip G Shah has 43 years of varied experience in the pharmaceutical industry and currently holds the following positions:

Advisory Positions:

  • Member of Medicines Transparency Alliance (MeTA), International Advisory Group (IAG), the UK Department for International Development (DFID).
  • Member of the Board of Advisors of Pharmabiz.com (Weekly).
  • Member of the Advisory Panel for the Business Briefing: PharmaGenerics, U.K.
  • Editor, Asia and India, Journal of Generic Medicines, U.K.

Trade Associations:

  • Member of the Management Committee of the International Generic Pharmaceutical Alliance (IGPA)
  • Secretary General of the Indian Pharmaceutical Alliance (IPA), an Association of 15 large research based national companies. Together they service about one-third of the domestic market, account for one-third of exports and contribute 90 per cent of R & D spending in the pharmaceutical industry
  • Co-Chairman of the FICCI's Committee on Pharmaceuticals

Independent Director:

Anuh Pharma Ltd., Mumbai

Consulting:

  • CEO, Vision Consulting Group, a firm specialized in strategic planning (http://www.vision-india.com. ).
  • Author of the first book on "Drug Pricing in India" and occasional contributor to business press, he graduated from the premier business school in India, Indian Institute of Management (IIM), Ahmedabad, and has been a guest faculty for their Management Development Programmes.

Before starting Vision in 1997, he was a Member of the Board of Directors of Pfizer-India where he worked for 30 years. He has represented Indian pharmaceutical industry at several international meetings and conferences.

Mr. Rajiv Lochan Jain (Non - Executive Director)

Mr. Rajiv Lochan Jain was born on Jan 1, 1951 in Kolkata. He is a Chemical Engineer from IIT Kharagpur and an MBA from Whittemore School of Business and Economics, UNH, USA.

Mr. Jain was a member on the Board of ICI India Limited for over 12 years and the Managing Director from April 2003 to May 2009. Mr. Jain successfully led the portfolio reshaping of ICI India from a diversified chemical Company to a focused and fastest growing player in the Paints business. Mr. Jain was also the Chairman of both ICI's Research Company in India and the joint-venture company of ICI and Orica, Australia.

Currently, he is the Executive Chairman of Performance Capital Partners LLP, advises global and local companies on their entry and growth strategies for India and serves on the Board of Goodyear India Limited and Tara Jewels Limited.

Steffen Roser (Non - Executive Director)

Mr. Steffen Roser obtained his Master's Degree in Business Administration from the Frankfurt University, Germany in 1988.

In year 1989, he started his professional career as a Controller with Procter & Gamble. He joined Fresenius Group in year 1994 as a Controller Corporate and since then has handled many critical assignments within the Fresenius group at different positions. Currently he is acting as the CFO of pharmaceutical division at Fresenius Kabi, Germany.

Mr. Karsten Peter Lerch (Director & CFO)

Mr. Karsten Peter Lerch holds a degree in Economics from Eberhard-Karls-University of Tübingen, Germany.

Mr. Lerch has more than 15 years of rich experience at an international level. He started his professional career as a business consultant with GMO Management Consulting Group in Düsseldorf with a focus on SAP and Controlling projects.

He has been associated with Fresenius Group since March 2014 and worked as the Director Compliance & Process Excellence at Fresenius Kabi Deutchland GmbH, Pharmaceuticals Division.

He has been associated with the Company as CFO since January 1, 2016 and appointed as Whole Time Director with the designation of "Director & CFO” with effect from February 25, 2016.

 

 

 


© All Copyright Reserved | Fresenius Kabi Oncology Limited 2012
This site is best viewed with a resolution of 1024x768 (or higher) and supports Microsoft Internet Explorer 8.0+ and Firefox 3.0+